http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
BeiGene Advances Leadership in CLL at ASH 2024 with New Data From Its Hematology Franchise Including BRUKINSA® and Novel Pipeline Assets
-
BeiGene and CLL Society Partner to Advance Test Before Treat™ Campaign, Promoting Biomarker Testing to Improve Patient Outcomes in CLL
-
BeiGene to Host Investor Webcast Highlighting Key Data from ASH and the San Antonio Breast Cancer Symposium on December 16, 2024
-
BeiGene (BGNE) Announces EU Approval of TEVIMBRA
-
European Commission Approves BeiGene’s TEVIMBRA for First-Line Treatment of Advanced/Metastatic Esophageal Squamous Cell Carcinoma and Gastric or Gastroesophageal Junction Cancer
-
BeiGene to Present at Upcoming Investor Conferences
-
BeiGene Announces Settlement of Litigation Against Generic Filer of BRUKINSA
-
BeiGene Unveils Proposed Name Change to BeOne Medicines, Reaffirming Its Mission to Unite Global Community Against Cancer
-
BeiGene Announces Third Quarter 2024 Financial Results and Corporate Updates
-
BeiGene to Present at the Jefferies London Healthcare Conference
-
BeiGene Highlights Innovative Hematology Portfolio Across B-cell Malignancies at ASH 2024
-
BeiGene (BGNE) Announces Passing of Director Donald Glazer
-
BeiGene Mourns Death of Beloved Board Member Donald Glazer
-
BeiGene Receives Positive CHMP Opinions for TEVIMBRA® as a First-Line Treatment for Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer and Esophageal Squamous Cell Carcinoma
-
BeiGene Highlights Waldenström’s Macroglobulinemia Innovation at IWWM 2024
-
BeiGene Provides Update on FDA Advisory Committee Vote on Benefit-Risk Profile of PD-1 Inhibitors, including TEVIMBRA®, for Treatment of ESCC and Gastric/GEJ Cancers
-
BeiGene (BGNE) Appoints Shalini Sharp to its Board
-
Global Oncology Innovator BeiGene Appoints Shalini Sharp to Board of Directors
-
BeiGene (BGNE) Receives Israeli Ministry of Health Approval for TEVIMBRA for the Treatment of Oesophageal Squamous Cell Carcinoma (OSCC) After Prior Chemotherapy
-
BeiGene Receives Israeli Ministry of Health Approval for TEVIMBRA® for the Treatment of Oesophageal Squamous Cell Carcinoma (OSCC) After Prior Chemotherapy
-
BeiGene (BGNE) Appoints Matt Shaulis as GM of North America
-
BeiGene Announces Updates to Commercial Leadership Team
-
BeiGene Highlights TEVIMBRA® Data in Lung and Gastrointestinal Cancers at ESMO 2024
-
BeiGene to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
-
BeiGene’s BGB-16673 Receives U.S. FDA Fast Track Designation for CLL/SLL
-
BeiGene Enters Next Phase of Global Growth with Announcement of Second Quarter 2024 Financial Results and Corporate Updates
-
BeiGene (BGNE) Opens Flagship U.S. Biologics Manufacturing and Clinical R&D Facility
-
BeiGene Opens Flagship U.S. Biologics Manufacturing and Clinical R&D Facility, Continues Global Expansion to Deliver Medicines to More Patients Around the World
-
BeiGene (BGNE) Appoints Aaron Rosenberg as CFO
-
BeiGene Announces Appointment of Aaron Rosenberg as Chief Financial Officer
-
BeiGene to Present New Data from SEQUOIA Study Evaluating BRUKINSA® plus Venetoclax in High-Risk First-Line CLL/SLL at EHA2024
-
BeiGene and NewBridge Pharmaceuticals FZ LLC Mutually Agree to Conclude BRUKINSA® (Zanubrutinib) Partnership in the Middle East and Africa (MENA) Region
-
BeiGene to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
-
BRUKINSA® Data at ASCO Underscore Differentiated Clinical Profile for Treatment of CLL and SLL
-
BeiGene Highlights New Hematology Portfolio and Pipeline Data at EHA2024
-
BeiGene Reports First Quarter 2024 Financial Results and Business Updates
-
BeiGene Demonstrates Global Progress in 2023 Responsible Business & Sustainability Report
-
Global Oncology Innovator BeiGene Highlights New Data across Hematology and Solid Tumor Portfolio at 2024 ASCO Annual Meeting
-
BeiGene (BGNE) Receives EU Approval for Tislelizumab
-
BeiGene Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer
-
BeiGene (BGNE) Receives FDA Approval for TEVIMBRA for the Treatment of Advanced or Metastatic ESCC After Prior Chemotherapy
-
BeiGene Receives FDA Approval for TEVIMBRA® for the Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy
-
First Doses of BRUKINSA® provided to Patients with Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries Under Collaboration of The Max Foundation, BeiGene, and the BeiGene Foundation
-
BeiGene (BGNE) Announces FDA Accelerated Approval of BRUKINSA
-
BeiGene Announces FDA Accelerated Approval of BRUKINSA for the Treatment of Relapsed or Refractory Follicular Lymphoma
-
BeiGene to Present Clinical and Preclinical Data from Broad Portfolio and Pipeline at AACR Annual Meeting 2024
-
BeiGene (BGNE) Announces New Efficacy Analysis Comparing BRUKINSA vs Acalabrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
-
BeiGene Announces New Efficacy Analysis Comparing BRUKINSA® vs Acalabrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
-
BeiGene to Present at Upcoming Investor Conferences
-
BeiGene's (BGNE) BLA for TEVIMBRA Accepted by FDA
